Open-label Study of Nelotanserin in Lewy Body Dementia With Visual Hallucinations or REM Sleep Behavior Disorder
Public ClinicalTrials.gov record NCT02871427. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-label Study of Nelotanserin in Patients With Lewy Body Dementia Who Have Frequent Visual Hallucinations or REM Sleep Behavior Disorder
Study identification
- NCT ID
- NCT02871427
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Axovant Sciences Ltd.
- Industry
- Enrollment
- 80 participants
Conditions and interventions
Conditions
Interventions
- Nelotanserin Drug
Drug
Eligibility (public fields only)
- Age range
- 50 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 19, 2016
- Primary completion
- Jan 16, 2019
- Completion
- Jan 16, 2019
- Last update posted
- Mar 26, 2019
2016 – 2019
United States locations
- U.S. sites
- 19
- U.S. states
- 13
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| US120 | Birmingham | Alabama | 35294 | — |
| US143 | Little Rock | Arkansas | 77205 | — |
| US114 | Boca Raton | Florida | 33486 | — |
| US180 | Maitland | Florida | 32751 | — |
| US154 | Ocala | Florida | 34471 | — |
| US113 | Orlando | Florida | 32806 | — |
| US152 | Ormond Beach | Florida | 32174 | — |
| US107 | Indianapolis | Indiana | 46202 | — |
| US132 | Lenexa | Kansas | 66214 | — |
| US103 | Rochester | Minnesota | 55905 | — |
| US129 | Lincoln | Nebraska | 68526 | — |
| US101 | Chapel Hill | North Carolina | 27514 | — |
| US147 | Fargo | North Dakota | 58103 | — |
| US111 | Cincinnati | Ohio | 45229 | — |
| US104 | Cleveland | Ohio | 44195 | — |
| US105 | Columbus | Ohio | 43210 | — |
| US173 | Lincoln | Rhode Island | 02865 | — |
| US128 | Memphis | Tennessee | 38163 | — |
| US131 | San Antonio | Texas | 78229 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02871427, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 26, 2019 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02871427 live on ClinicalTrials.gov.